PL354268A1 - Kierowanie leku za pośrednictwem integrynyKierowanie leku za pośrednictwem integryny - Google Patents
Kierowanie leku za pośrednictwem integrynyKierowanie leku za pośrednictwem integrynyInfo
- Publication number
- PL354268A1 PL354268A1 PL00354268A PL35426800A PL354268A1 PL 354268 A1 PL354268 A1 PL 354268A1 PL 00354268 A PL00354268 A PL 00354268A PL 35426800 A PL35426800 A PL 35426800A PL 354268 A1 PL354268 A1 PL 354268A1
- Authority
- PL
- Poland
- Prior art keywords
- sub
- integrin
- drug targeting
- cytostatic
- beta
- Prior art date
Links
- 102000006495 integrins Human genes 0.000 title abstract 2
- 108010044426 integrins Proteins 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 239000000824 cytostatic agent Substances 0.000 abstract 3
- 230000001085 cytostatic effect Effects 0.000 abstract 3
- 229940123038 Integrin antagonist Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Indole Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39216799A | 1999-09-08 | 1999-09-08 | |
| US60677200A | 2000-06-29 | 2000-06-29 | |
| PCT/EP2000/008361 WO2001017563A2 (en) | 1999-09-08 | 2000-08-28 | Integrin-mediated drug targeting |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL354268A1 true PL354268A1 (pl) | 2003-12-29 |
Family
ID=27013781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL00354268A PL354268A1 (pl) | 1999-09-08 | 2000-08-28 | Kierowanie leku za pośrednictwem integrynyKierowanie leku za pośrednictwem integryny |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060189544A1 (pl) |
| EP (1) | EP1235595B8 (pl) |
| JP (1) | JP2003508497A (pl) |
| CN (1) | CN1402643A (pl) |
| AT (1) | ATE438413T1 (pl) |
| AU (1) | AU773781B2 (pl) |
| BR (1) | BR0013883A (pl) |
| CA (1) | CA2383981A1 (pl) |
| DE (1) | DE60042700D1 (pl) |
| ES (1) | ES2330079T3 (pl) |
| HU (1) | HUP0203899A3 (pl) |
| MX (1) | MXPA02002488A (pl) |
| NZ (1) | NZ517620A (pl) |
| PL (1) | PL354268A1 (pl) |
| RU (1) | RU2002109215A (pl) |
| WO (1) | WO2001017563A2 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1219305A1 (en) * | 2000-12-27 | 2002-07-03 | Bayer Aktiengesellschaft | Conjugates of integrin receptor antagonists and a cytostatic agent having specifically cleavable linking units |
| EP1238678A1 (en) * | 2001-03-08 | 2002-09-11 | Bayer Aktiengesellschaft | Enzyme-activated cytostatic conjugates with integrin ligands |
| ITRM20040241A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 20 con antagonisti delle integrine. |
| ITRM20040240A1 (it) * | 2004-05-13 | 2004-08-13 | Ist Naz Stud Cura Dei Tumori | Camptotecine coniugate in posizione 7 con antagonisti delle integrine. |
| CN105566338B (zh) * | 2014-10-08 | 2017-11-21 | 兰州大学 | 一种喜树碱类化合物及其制备方法和用途 |
| CN108456154A (zh) * | 2018-04-13 | 2018-08-28 | 昆明理工大学 | 一种n-叔丁氧羰基烃基胍的制备方法 |
| EP4412656A1 (en) * | 2021-10-04 | 2024-08-14 | Vincerx Pharma GmbH | Compounds, pharmaceutical compositions, and methods for the treatment, prevention, or management of hyperproliferative disorders |
| KR20240105377A (ko) * | 2021-10-04 | 2024-07-05 | 빈서스 파마 게엠베하 | 과증식성 질환의 치료, 예방 또는 관리를 위한 화합물, 약학 조성물 및 방법 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3353209B2 (ja) * | 1992-04-03 | 2002-12-03 | ジェネンテク，インコーポレイテッド | αｖβ３インテグリンに対する抗体 |
| WO1997039021A1 (en) * | 1995-12-21 | 1997-10-23 | The Scripps Research Institute | Targeted therapeutic or diagnostic agents and methods of making and using same |
-
2000
- 2000-08-28 ES ES00965901T patent/ES2330079T3/es not_active Expired - Lifetime
- 2000-08-28 RU RU2002109215/15A patent/RU2002109215A/ru not_active Application Discontinuation
- 2000-08-28 BR BR0013883-5A patent/BR0013883A/pt not_active IP Right Cessation
- 2000-08-28 CA CA002383981A patent/CA2383981A1/en not_active Abandoned
- 2000-08-28 AT AT00965901T patent/ATE438413T1/de not_active IP Right Cessation
- 2000-08-28 WO PCT/EP2000/008361 patent/WO2001017563A2/en active Search and Examination
- 2000-08-28 AU AU76487/00A patent/AU773781B2/en not_active Ceased
- 2000-08-28 PL PL00354268A patent/PL354268A1/pl not_active Application Discontinuation
- 2000-08-28 MX MXPA02002488A patent/MXPA02002488A/es unknown
- 2000-08-28 DE DE60042700T patent/DE60042700D1/de not_active Expired - Lifetime
- 2000-08-28 NZ NZ517620A patent/NZ517620A/en unknown
- 2000-08-28 CN CN00814704A patent/CN1402643A/zh active Pending
- 2000-08-28 HU HU0203899A patent/HUP0203899A3/hu unknown
- 2000-08-28 EP EP00965901A patent/EP1235595B8/en not_active Expired - Lifetime
- 2000-08-28 JP JP2001521351A patent/JP2003508497A/ja active Pending
-
2006
- 2006-04-07 US US11/399,985 patent/US20060189544A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2383981A1 (en) | 2001-03-15 |
| JP2003508497A (ja) | 2003-03-04 |
| AU7648700A (en) | 2001-04-10 |
| ATE438413T1 (de) | 2009-08-15 |
| HUP0203899A2 (hu) | 2003-02-28 |
| ES2330079T3 (es) | 2009-12-04 |
| NZ517620A (en) | 2004-02-27 |
| EP1235595B1 (en) | 2009-08-05 |
| BR0013883A (pt) | 2002-05-07 |
| HUP0203899A3 (en) | 2004-09-28 |
| EP1235595B8 (en) | 2009-10-07 |
| DE60042700D1 (de) | 2009-09-17 |
| WO2001017563A2 (en) | 2001-03-15 |
| MXPA02002488A (es) | 2002-08-12 |
| CN1402643A (zh) | 2003-03-12 |
| RU2002109215A (ru) | 2003-12-10 |
| US20060189544A1 (en) | 2006-08-24 |
| AU773781B2 (en) | 2004-06-03 |
| EP1235595A2 (en) | 2002-09-04 |
| WO2001017563A3 (en) | 2002-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL140710A0 (en) | Pulmonary delivery of active agents | |
| AU7576896A (en) | Lipopolyamines as transfection agents and their pharmaceutical applications | |
| EP0993831A3 (en) | Compounds and compositions for delivering active agents | |
| AU6628496A (en) | Polyether block copolymer micellar compositions for targeting biological agents | |
| MX9702307A (es) | Pirrolo (2,3-d)pirimidinas y su uso. | |
| CA2093798A1 (en) | Pyridine and pyridine n-oxide derivatives of diaryl methyl piperidines or piperazines, and compositions and methods of use thereof | |
| FI962154A (fi) | Koostumus terapeuttisten tuotteiden in vivo valmistusta varten | |
| WO2000015231A8 (en) | Adenosine a3 receptor modulators | |
| AU1416501A (en) | Novel phenylalanine derivatives | |
| AU2845599A (en) | Pharmaceutical compositions and their use | |
| MX9709146A (es) | Compuestos novedosos, preparacion y uso de los mismos. | |
| AU5596298A (en) | Integrin antagonists | |
| AP2000001947A0 (en) | Novel crystalline forms of an antiviral benzidazole compound. | |
| BR0007514A (pt) | Macrolìdeos com atividade anti-inflamatória | |
| PL354268A1 (pl) | Kierowanie leku za pośrednictwem integrynyKierowanie leku za pośrednictwem integryny | |
| BG105885A (en) | Remedies for joint diseases | |
| YU72194A (sh) | Injekcione suspenzije sa produženim dejstvom i postupak za proizvodnju istih | |
| TR200001102T2 (tr) | İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları. | |
| IT1270618B (it) | Proteine ad attivita' antitumorale | |
| ATE201680T1 (de) | 2,3,4,5-tetrahydro-1h-3-benzazepin säure- additions-salze | |
| SE9902056D0 (sv) | An integrin heterodimer and an alpha subunit thereof | |
| AU9270598A (en) | Hydrazono-benzazulene derivatives, pharmaceutical compositions and in termediates | |
| IT1306147B1 (it) | Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali | |
| AU5685300A (en) | Solid preparations containing paroxetine | |
| MX9702659A (es) | Pirroliltetrahidrobenzoquinoxalindionas, su preparacion y uso. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |